CSAdd image
Cagrilintide + Semaglutide Blend
Weight LossBlendAlso known as: CagriSema
Components: Cagrilintide, Semaglutide
A blend pairing the amylin analog Cagrilintide with the GLP-1 agonist Semaglutide for additive metabolic effects. Active clinical investigation.
Half-life
168 h
Common dose
250 – 2400 mcg
Dosing frequency
Weekly
Administration
Subcutaneous
How it works
Cagrilintide adds amylin-mediated satiety and gastric slowing on top of GLP-1's effects. Phase-3 trials are evaluating ~20%+ body-weight loss potential.
Protocol notes
Trial protocols use 1:1 cagrilintide:semaglutide weekly titration up to 2.4 mg of each weekly.
Reported side effects
GI effects similar to either component, sometimes more pronounced; nausea, vomiting.